Corbus Pharmaceuticals said the last patient completed the final visit in its CANYON-1 Phase 1b obesity trial, keeping CRB-913 topline data on track for Septemb

Corbus Pharmaceuticals said the last patient completed the final visit in its CANYON-1 Phase 1b obesity trial, keeping CRB-913 topline data on track for September 2026. The update adds to recent pipeline progress, including FDA clearance for a CRB-701 study.